NASDAQ:CHMA - Chiasma Stock Price, Forecast & News

Chiasma trades on the NASDAQ under the ticker symbol "CHMA."

Chiasma Inc (NASDAQ:CHMA) posted its quarterly earnings data on Tuesday, November, 5th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.01. View Chiasma's Earnings History.

Chiasma is scheduled to release their next quarterly earnings announcement on Friday, March 13th 2020. View Earnings Estimates for Chiasma.

5 brokers have issued twelve-month target prices for Chiasma's stock. Their forecasts range from $11.00 to $18.00. On average, they anticipate Chiasma's stock price to reach $13.25 in the next year. This suggests a possible upside of 188.0% from the stock's current price. View Analyst Price Targets for Chiasma.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chiasma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chiasma.

Media stories about CHMA stock have been trending very positive this week, InfoTrie reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Chiasma earned a news sentiment score of 3.1 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Chiasma.

Chiasma saw a decline in short interest in January. As of January 31st, there was short interest totalling 1,600,000 shares, a decline of 10.1% from the January 15th total of 1,780,000 shares. Based on an average daily volume of 275,500 shares, the days-to-cover ratio is presently 5.8 days. Currently, 5.3% of the company's stock are short sold. View Chiasma's Current Options Chain.

Some companies that are related to Chiasma include Retrophin (RTRX), ANI Pharmaceuticals (ANIP), Provention Bio (PRVB), Arcus Biosciences (RCUS), DiaMedica Therapeutics (DMCAF), Frequency Therapeutics (FREQ), Vanda Pharmaceuticals (VNDA), Eagle Pharmaceuticals (EGRX), Aprea Therapeutics (APRE), G1 Therapeutics (GTHX), Cara Therapeutics (CARA), Phoenix Tree (IMAB), RAPT Therapeutics (RAPT), Omeros (OMER) and Atreca (BCEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Chiasma investors own include Arbutus Biopharma (ABUS), Bausch Health Companies (BHC), GW Pharmaceuticals PLC- (GWPH), BioDelivery Sciences International (BDSI), Alnylam Pharmaceuticals (ALNY), Agile Therapeutics (AGRX), Exelixis (EXEL), Skyworks Solutions (SWKS), Progenics Pharmaceuticals (PGNX) and SCYNEXIS (SCYX).

(CHMA) raised $76 million in an initial public offering (IPO) on Thursday, July 16th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Barclays and Cowen and Company acted as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

Chiasma's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Point72 Asset Management L.P. (3.57%), Ikarian Capital LLC (2.63%), State Street Corp (1.42%), Renaissance Technologies LLC (1.37%), Geode Capital Management LLC (1.07%) and J. Goldman & Co LP (0.83%). Company insiders that own Chiasma stock include Mark J Fitzpatrick, Roni Mamluk, Scott Minick and William Ludlam. View Institutional Ownership Trends for Chiasma.

CHMA stock was sold by a variety of institutional investors in the last quarter, including J. Goldman & Co LP and Point72 Asset Management L.P.. View Insider Buying and Selling for Chiasma.

CHMA stock was acquired by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, State Street Corp, Geode Capital Management LLC, California Public Employees Retirement System, Barclays PLC, ProShare Advisors LLC, UBS Group AG and Virtu Financial LLC. Company insiders that have bought Chiasma stock in the last two years include Mark J Fitzpatrick, Scott Minick and William Ludlam. View Insider Buying and Selling for Chiasma.

Shares of CHMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CHMA stock can currently be purchased for approximately $4.60.

Chiasma has a market capitalization of $193.29 million. The biotechnology company earns $-31,260,000.00 in net income (profit) each year or ($1.28) on an earnings per share basis. Chiasma employs 18 workers across the globe.View Additional Information About Chiasma.

The official website for Chiasma is http://www.chiasmapharma.com/.

Chiasma's mailing address is 460 Totten Pond Road Suite 530, Waltham MA, 02451. The biotechnology company can be reached via phone at 617-928-5300 or via email at [email protected]